Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Share information
Events & Presentations
Financial reports
Financial calendar
Shareholder meetings
Shareholder information
Analyst coverage
Corporate governance
ESG
Newsroom
Press Releases
Image library
Glossary
Careers
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
22/07/2021
Using an Inflammatory Chemokine Linked to the Antigen Generates a Rapid, Strong and Broad Immune Response
26/04/2021
Targeting antigens to antigen presenting cells induce effective anti-tumor efficacy as monotherapy and as combination therapy
26/01/2021
Single dose immunization with a COVID-19 DNA vaccine encoding a chimeric homodimeric protein targeting receptor binding domain (RBD) to antigen-presenting cells induces rapid, strong and long-lasting neutralizing IgG, Th1 dominated CD4+ T cells and strong CD8+ T cell responses in mice
17/09/2020
A MULTI-CENTRE, OPEN-LABEL PHASE 2 TRIAL OF THE COMBINATION OF VB10.16 AND ATEZOLIZUMAB IN PATIENTS WITH ADVANCED OR RECURRENT, NON-RESECTABLE HPV16 POSITIVE CERVICAL CANCER
19/03/2020
UPDATE FROM VACCIBODY’S CLINICAL TRIAL WITH THE PERSONALIZED CANCER NEOANTIGEN VACCINE, VB10.NEO | San Diego, March 2020
Pages:
1
2
3
4
5
6
7
8
9
10
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
